Intelligent Surgical Unit Enables Augmented Intelligence on the Senhance System

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sep. 23, 2020-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Hackensack Meridian Health Pascack Valley Medical Center, a hospital in New Jersey, successfully completed its first surgical procedures using the Intelligent Surgical Unit^TM (ISU™). The technology previously received FDA clearance, and currently enables machine vision capabilities on the Senhance^Ⓡ Surgical System. The patients were treated by Dr. Amit Trivedi, Chair of Surgery at Hackensack Meridian Health Pascack Valley Medical Center, and his team in multiple general surgery procedures.

“Augmented intelligence technologies, including machine vision and machine learning, will play an increasingly significant role in surgery. These technologies process the image and apply intelligence to extend the surgeon’s ability to utilize information from the surgical field of view. We are excited to be at the forefront of the innovation curve by developing these technologies for surgeons and patients,” said Anthony Fernando, TransEnterix President and CEO. “The introduction of machine vision capabilities represents an important step in our goal to reduce variability in surgery and improve surgical outcomes by supporting surgeon decision making and reducing cognitive fatigue.”

The Intelligent Surgical Unit adds augmented intelligence to the Senhance Surgical System. Currently, the ISU enables machine vision driven control of the camera which allows the system to recognize certain objects and locations in the surgical field, and provides seamless sharing of the surgeon console’s view across all members of the operating room in real-time, all the while allowing the surgeon to maintain full control. These initial capabilities are foundational to planned future augmented intelligence features such as scene cognition and surgical image analytics that are expected to further enhance the digital laparoscopic experience with Senhance. The ISU is compatible with the global installed base of Senhance Surgical Systems and with third-party vision systems that are currently supported by Senhance.

“The Intelligent Surgical Unit provides me with capabilities that I’ve never before experienced in performing laparoscopic or robotic surgery. The system can easily recognize and track different robotic or manual instruments to move the camera efficiently. These capabilities make controlling visualization in complex surgery simpler and more efficient,” said Dr. Amit Trivedi. “In addition, the ISU enabled my surgical team to see and experience what I was seeing on the surgeon console so they could proactively assist me and play an active role in the Digital Laparoscopic experience. I believe the ISU will add new benefits to what we can do in surgery, and is the start of an era where augmented intelligence can be integrated in real-time during an operation to benefit the surgeon and the patient.”

About TransEnterix

At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance®️ Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: https://Senhance.com/. Now available for sale in the US, the EU, Japan, and select other countries. For a complete list of indications for use, please visit: https://www.transenterix.com/indications-for-use/.

Forward-Looking Statements

This press release includes statements relating to the Senhance System and the first usage of machine vision capabilities in robotic surgery. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the ISU’s augmented intelligence, machine vision and machine learning in digital surgery will be the primary way technology can add new value to surgical procedures and whether the ISU will add new benefits to what can be done in surgery and is the start of an era where augmented intelligence can be integrated in real-time during an operation to benefit the surgeon and the patient. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005174/en/

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com

Source: TransEnterix, Inc.